Regenicin, Inc.

470 Park Avenue South, 16th Floor
10016 New York City
USA

Contact

About Regenicin

Regenicin, Inc. is a clinical-stage company developing next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. Regenicin is a publicly traded company, with headquarters in New York, NY.

News about Regenicin

27-Aug-2010 | people

Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors

Rubinfeld expected to assist with FDA approval process for autologous cultured skin substitute, PermaDerm(TM)

Read news

Show more news about Regenicin

Get the life science industry in your inbox

Regenicin, Inc.

About Regenicin

News about Regenicin

Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors

Here you will find Regenicin, Inc.

Regenicin, Inc.